Piramal Pharma Limited — Board Meeting, 28-04-2026: Outcome of Board Meeting

Piramal Pharma's board approved audited financial results, reporting a consolidated net loss of Rs 8.82 Cr for Q4 FY26 & Rs 325.94 Cr for FY26. Key re-appointments include Nandini Piramal as Chairperson & Executive Director, Peter DeYoung as Executive Director, and two Independent Directors. Maneesh Sharma joins as new Company Secretary.